Back to News
Nov 25, 2025 12:00 PM

Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients

Novo Nordisk A/S (NYSE:NVO) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes.

The update marks the first evaluation of amycretin in people with type 2 diabetes.

Novo Nordisk is planning to initiate a phase 3 development program with amycretin for adults with type 2 diabetes in 2026. In June, the company said it planned to initiate a phase 3 development for amycretin for adults with overweight or obesity in the first quarter of 2026.

The trial evaluated once-weekly subcutaneous amycretin and once-daily oral amycretin compared with placebo in 448 patients with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor as standard of care.

Approximately 40% of all participants were using an SGLT2 inhibitor before initiating the trial.

SGLT2 inhibitors ...